Arcutis Biotherapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Arcutis Biotherapeutics, Inc. (ARQT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-140.04-262.14-311.46-206.36-135.68
Depreciation & Amortization2.601.91-1.020.450.12
Stock Based Compensation41.7338.8132.6823.897.94
Change in Working Capital-15.08-22.84-9.743.6214.13
Change in Accounts Receivable-47.26-17.35-8.460.000.00
Change in Inventory-0.40-5.62-7.510.000.00
Change in Accounts Payable2.233.151.570.255.67
Change in Other Working Capital30.35-3.684.233.388.46
Other Operating Activities-1.3735.2064.490.310.33
Net Cash from Operating Activities-112.16-247.06-257.72-174.63-113.03
Investing Activities
Capital Expenditures-0.14-0.437.83-1.00-0.32
Acquisitions0.000.00-15.450.000.00
Purchases of Investments-254.82180.66-63.92-74.96-181.50
Sales/Maturities of Investments288.78-225.84-63.92217.55-181.50
Other Investing Activities-5.000.000.000.000.00
Net Cash from Investing Activities28.82180.23-87.20-75.95-181.82
Financing Activities
Debt Repayment-100.000.00-2.19-1.640.00
Common Stock Issued161.68101.32161.59209.60298.15
Other Financing Activities4.520.0014.46-1.640.00
Net Cash from Financing Activities66.20101.32301.80281.95298.15
Summary
Effect of Forex Changes on Cash-0.24-0.050.000.000.00
Net Change in Cash-17.3734.45-43.1231.373.29
Cash at Beginning of Period89.3254.8897.9966.6263.34
Cash at End of Period71.95-472.8754.8897.9966.62
Free Cash Flow-112.30-247.06-265.55-175.62-113.35
Supplemental Disclosures
Interest Paid22.2125.4512.640.140.00